We are live on ! Find out more
CM

CM Management Portfolio holdings

AUM $120M
1-Year Est. Return 37.12%
This Fund
S&P 500
This Quarter Est. Return
-5.23%
1 Year Est. Return
+37.12%
3 Year Est. Return
+141.34%
5 Year Est. Return
+139.46%
10 Year Est. Return
–
AUM
$99.5M
AUM Growth
-$12.5M
Cap. Flow
-$3.66M
Cap. Flow %
-3.68%
Top 10 Hldgs %
41.5%
Holding
62
New
5
Increased
25
Reduced
4
Closed
8

Top Buys

Rank Stock Value
1
CYTK icon
Cytokinetics
CYTK
+$1.84M
2
IOVA icon
Iovance Biotherapeutics
IOVA
+$1.03M
3
HRI icon
Herc Holdings
HRI
+$852K
4
SWK icon
Stanley Black & Decker
SWK
+$843K
5
WBD icon
Warner Bros
WBD
+$837K

Top Sells

Rank Stock Value
1
RPRX icon
Royalty Pharma
RPRX
+$4.08M
2
CPA icon
Copa Holdings
CPA
+$2.64M
3
B
Barrick Mining
B
+$1.94M
4
CLPT icon
ClearPoint Neuro
CLPT
+$1.79M
5
PAAS icon
Pan American Silver
PAAS
+$1.62M

Sector Composition

Rank Sector Weight
1 Healthcare 36.19%
2 Materials 10.41%
3 Industrials 10.18%
4 Technology 9.3%
5 Financials 9.07%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CHRS icon
26
Coherus Oncology
CHRS
$217M
$1.73M 1.74%
2,147,500
+97,500
+5% +$112K
IOVA icon
27
Iovance Biotherapeutics
IOVA
$2.23B
$1.67M 1.67%
500,000
+200,000
+67% +$1.03M
WBD icon
28
Warner Bros
WBD
$64.6B
$1.61M 1.62%
150,000
+80,000
+114% +$837K
CYTK icon
29
Cytokinetics
CYTK
$11B
$1.61M 1.62%
+40,000
New +$1.84M
AVIR icon
30
Atea Pharmaceuticals
AVIR
$379M
$1.5M 1.5%
500,000
+200,000
+67% +$624K
COHU icon
31
Cohu
COHU
$2.39B
$1.47M 1.48%
100,000
+30,000
+43% +$624K
HRTX icon
32
Heron Therapeutics
HRTX
$86.3M
$1.32M 1.33%
600,000
-100,000
-14% -$194K
COYA icon
33
Coya Therapeutics
COYA
$99.7M
$1.29M 1.3%
200,000
+40,000
+25% +$253K
XOMA
34
DELISTED
Xoma
XOMA
$1.28M 1.28%
64,000
+9,000
+16% +$217K
ACAD icon
35
Acadia Pharmaceuticals
ACAD
$4.25B
$1.25M 1.25%
75,000
+5,000
+7% +$90.8K
SVC
36
Service Properties Trust
SVC
$1.1B
$1.17M 1.18%
90,000
– –
DIT icon
37
AMCON Distributing
DIT
$63.4M
$1.03M 1.03%
13,131
+631
+5% +$54.1K
CTSO icon
38
Cytosorbents Corp
CTSO
$22.6M
$954K 0.96%
954,076
+254,076
+36% +$268K
ELDN icon
39
Eledon Pharmaceuticals
ELDN
$276M
$932K 0.94%
275,000
– –
SWK icon
40
Stanley Black & Decker
SWK
$14.2B
$769K 0.77%
+10,000
New +$843K
LTRN icon
41
Lantern Pharma
LTRN
$35.1M
$708K 0.71%
200,000
– –
HRI icon
42
Herc Holdings
HRI
$5.43B
$671K 0.67%
+5,000
New +$852K
HAS icon
43
Hasbro
HAS
$12.6B
$615K 0.62%
10,000
-10,000
-50% -$605K
NKTR icon
44
Nektar Therapeutics
NKTR
$2.39B
$544K 0.55%
53,333
+3,333
+7% +$43.5K
FEMY icon
45
Femasys
FEMY
$11.2M
$531K 0.53%
21,250
– –
CRIS icon
46
Curis
CRIS
$9.53M
$504K 0.51%
12,000
+1,000
+9% +$61.9K
OSTX
47
OS Therapies Inc
OSTX
$67.7M
$462K 0.46%
300,000
+189,956
+173% +$446K
DELL icon
48
Dell
DELL
$283B
$456K 0.46%
+5,000
New +$529K
ELTX icon
49
Elicio Therapeutics
ELTX
$78.8M
$339K 0.34%
55,000
+15,000
+38% +$116K
ASRT
50
DELISTED
Assertio
ASRT
$320K 0.32%
31,667
+5,000
+19% +$59.6K
1
2
3

Similar funds

CC
Commons Capital Needham, Massachusetts $120M AUM 31.45% 1-Year Est. Return
DG
Dala Group Hoffman Estates, Illinois $120M AUM
ACM
AIHC Capital Management Central $120M AUM
WAG
Windsor Advisory Group Columbus, Ohio $120M AUM 4.29% 1-Year Est. Return
BCWM
Ball & Co Wealth Management Franklin, Tennessee $120M AUM 21.28% 1-Year Est. Return
WF
WealthPoint Financial Cramerton, North Carolina $119M AUM
SA
SJBenen ADVISORY Chapel Hill, North Carolina $120M AUM
SRL
Scientech Research LLC Jersey City, New Jersey $120M AUM 73.62% 1-Year Est. Return

CM Management's Q1 2025 Portfolio in Review

As of Q1 2025, CM Management held 62 positions worth $99.5M, down 11% from $112M the previous quarter. Its ten largest holdings account for 41% of the portfolio.

CM Management withdrew a net $3.66M in Q1 2025, closing 8 positions and reducing 4 holdings. Its most notable exit was Royalty Pharma, an estimated $4.08M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 36% of assets, down from 40% a quarter earlier, followed by Materials and Industrials.

Against the trend, CM Management opened a new position in Cytokinetics worth $1.61M.

  • CM Management's largest Q1 2025 buy was Cytokinetics: 40,000 shares worth $1.61M.
  • CM Management added most to Iovance Biotherapeutics in Q1 2025, an estimated $1.03M increase.
  • CM Management's biggest Q1 2025 reduction was ClearPoint Neuro, cutting an estimated $1.79M.
  • CM Management fully exited Royalty Pharma in Q1 2025, selling an estimated $4.08M.
  • CM Management's ten largest holdings make up 41% of its $99.5M portfolio in Q1 2025.
  • CM Management opened 5 new positions and closed 8 in Q1 2025.
  • CM Management's portfolio value fell 11% quarter-over-quarter to $99.5M.

Based on CM Management's 13F filing for Q1 2025, filed 9 May 2025.